advertisement
Glaucoma, the second leading cause of blindness worldwide, is a chronic, incurable disease. The principal aim of medical treatment is to preserve vision through reduction in levels of intraocular pressure (IOP). A variety of ocular hypotensive agents are currently in use, with many patients requiring more than 1 drug to achieve sufficient lowering of IOP. These combinations often entail complex scheduling, with resultant difficulties in patient compliance that may be obviated through the use of fixed combination (FC) formulations. The FC ophthalmic solution containing 0.005% latanoprost, a prostaglandin, and 0.5% timolol, a beta-blocker, administered as one drop once-daily, combines two mechanisms of action to reduce IOP. Latanoprost acts principally through increasing uveoscleral outflow, while timolol decreases the rate of production of aqueous humor by the ciliary epithelium. Clinical trials have demonstrated that FC latanoprost/timolol is as effective in lowering IOP as the concomitant use of its two constituents, and is equivalent or superior to other available fixed or unfixed combinations. Moreover, it has a favorable safety profile, equivalent to that of its individual components. Given the convenience of once-daily dosing, this FC formulation provides a safe and effective option for patients who cannot achieve adequate lowering of IOP through monotherapy. LA: Spanish
Dr. R.M. Feldman, Houston Medical School, Department of Ophthalmology and Visual Science, Hermann Eye Center, 6411 Fannin, Houston, TX 77030, USA. rmfeldman@swbell.net
11.13.4 Betablocker and prostaglandin (Part of: 11 Medical treatment > 11.13 Combination therapy)
9.2.3 Open angle glaucoma with elevated IOP (Part of: 9 Clinical forms of glaucomas > 9.2 Primary open angle glaucomas)
9.2.1 Ocular hypertension (Part of: 9 Clinical forms of glaucomas > 9.2 Primary open angle glaucomas)